, Tableau 3-Effets indésirables très fréquents (++ : ? 1/10) et fréquents (+ : de ? 1/100 à < 1/10) des différentes

, Annexe 1 (suite)-Risque relatif de cancer du sein en fonction du facteur de risque-HAS 2012

, Annexe 2-Planche illustrant la production d'oestrogènes chez la femme-C.Dupuis Annexe 3-Planche illustrant le mécanismes d

, Annexe 5-Planche illustrant le mécanisme d'action des inhibiteurs de l'aromatase-C.Dupuis Annexe 6-Planche « à trous » sur le mécanisme d'action des inhibiteurs de l'aromatase

, Dupuis Annexe 7 (suite)-Cartes recto-verso des idées reçues utilisées lors de l'atelier d'ETPC.Dupuis Annexe 8 (suite)-Cartes recto-verso des effets indésirables utilisées lors de l'atelier d'ETPC.Dupuis Annexe 8 (suite)-Cartes recto-verso des effets indésirables utilisées lors de l, Annexe 7-Cartes recto-verso des idées reçues utilisées lors de l'atelier d'ETP-C

, Annexe 9-Questionnaire de satisfaction distribué aux patientes à la fin de l'atelierC

, Annexe 10-Fiche Médicament de l'ARIMIDEX® remise aux patientes à la fin de l'atelierOMEDIT Normandie

, Annexe 11-Fiche Médicament du FEMARA® remise aux patientes à la fin de l'atelierOMEDIT Normandie

, Annexe 12-Fiche Médicament de l'AROMASINE® remise aux patientes à la fin de l'atelierOMEDIT Normandie

, Annexe 13-Fiche Médicament du Tamoxifène remise aux patientes à la fin de l'atelierOMEDIT Normandie

, Annexe 15-Evaluation de l'observance d'un traitement médicamenteux (Score de Girerd)Assurance Maladie

, Annexe 16-Affiche utilisée pour communiquer auprès des patientes de l'existence d'un atelier d'éducation thérapeutique sur l

S. B. Edge and C. C. Compton, The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM, Ann Surg Oncol, vol.17, issue.6, pp.1471-1475

,

C. W. Elston and I. O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.19, issue.5, pp.403-413, 1991.

. Disponible,

C. H. Lee, D. D. Dershaw, D. Kopans, P. Evans, B. Monsees et al., Breast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast Cancer, J Am Coll Radiol, vol.7, issue.1, pp.18-27

N. Leone, N. Voirin, and L. Roche, Projections de l ' incidence et de la mortalité par cancer en France en, Invs, pp.1-2, 2015.

M. Colonna, E. Chatignoux, L. Remontet, N. Mitton, A. Belot et al., Estimation de l'incidence départementale des cancers en France métropolitaine, 2008.

, Étude à partir des données des registres des cancers du réseau Francim et des bases de données médico-administratives, vol.53, 2015.

M. Nadji, C. Gomez-fernandez, P. Ganjei-azar, and A. R. Morales, Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers, Am J Clin Pathol, vol.123, issue.1, pp.21-28, 2005.

C. L. Arteaga, M. X. Sliwkowski, C. K. Osborne, E. A. Perez, F. Puglisi et al., Treatment of HER2-positive breast cancer: current status and future perspectives, Nat Rev Clin Oncol, vol.9, issue.1, pp.16-32, 2011.

H. Autorité-de-santé, Dépistage du cancer du sein en France : identification des femmes à haut risque et modalités de dépistage Volet 1. Recommandations de santé publique, 2012.

. Disponible,

F. Binder-foucard, A. Belot, and P. Delafosse, Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Inst Veill Sanit, vol.122, 2013.

, Principales recommandations de prise en charge des femmes porteuses d'une mutation de BRCA1 ou BRCA2, 2009.

S. J. Mandriota, M. Tenan, P. Ferrari, and A. P. Sappino, Aluminium chloride promotes tumorigenesis and metastasis in normal murine mammary gland epithelial cells, Int J Cancer, vol.139, issue.12, pp.2781-90, 2016.

H. Fritz, D. Seely, G. Flower, B. Skidmore, R. Fernandes et al., Red Clover, and Isoflavones and Breast Cancer: A Systematic Review. Shioda T, éditeur. PLoS One, vol.8, 2013.

R. A. Karasneh, L. J. Murray, and C. R. Cardwell, Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies, Int J cancer [Internet]. 1 mars, vol.140, issue.5, pp.1035-1076, 2017.

D. Braithwaite, M. Izano, D. H. Moore, M. L. Kwan, M. C. Tammemagi et al., Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review, Breast Cancer Res Treat, vol.136, issue.2, pp.521-554, 2012.

M. Sollie and C. Bille, Smoking and mortality in women diagnosed with breast cancer-a systematic review with meta-analysis based on 400,944 breast cancer cases. Gland Surg, vol.6, pp.385-93, 2017.

C. C. Going, L. Alexandrova, K. Lau, C. Y. Yeh, D. Feldman et al., Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial

, Breast Cancer Res Treat, issue.7, p.12, 2017.

. Disponible,

Y. Kim and Y. Je, Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis, p.12, 2014.

. Disponible,

P. J. Hardefeldt, R. Penninkilampi, S. Edirimanne, and G. D. Eslick, Physical Activity and Weight Loss Reduce the Risk of Breast Cancer: A Meta-analysis of 139 Prospective and Retrospective Studies, Clin Breast Cancer, issue.17, 2017.

. Disponible,

M. D. Holmes, W. Y. Chen, D. Feskanich, C. H. Kroenke, and G. A. Colditz, Physical Activity and Survival After Breast Cancer Diagnosis, JAMA, vol.25, issue.2005, p.2479

. Vidal, Monographie du NOLVADEX (Tamoxifène) 20 mg cp

. Vidal, Monographie du FASLODEX (Fulvestrant) 250 mg sol inj-Synthèse

. Vidal, Monographie du FARESTON (Torémifène) 60 mg cp

Y. Jin, Z. Desta, V. Stearns, B. Ward, H. Ho et al., CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment, J Natl Cancer Inst, vol.97, issue.1, pp.30-39, 2005.

E. Davies, C. Godwin, J. Gray, R. Clarke, M. Cutter et al., Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, 27 août, vol.378, issue.9793, pp.771-84, 2011.

J. R. Garreau, T. Delamelena, D. Walts, K. Karamlou, and N. Johnson, Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective, Am J Surg, vol.192, issue.4, pp.496-504, 2006.

. Vidal, Monographie de l'AROMASINE (Exemestane) 25 mg cp enr, p.25

. Vidal, Monographie de l'ARIMIDEX (anastrozole) 1 mg cp pellic

. Vidal, Monographie du FEMARA (létrozole) 2,5 mg cp pellic

J. Cuzick, I. Sestak, M. Baum, A. Buzdar, A. Howell et al., Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol [Internet], vol.11, issue.12, pp.70257-70263, 2010.

M. M. Regan, P. Neven, A. Giobbie-hurder, A. Goldhirsch, B. Ejlertsen et al., Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up, Lancet Oncol, vol.12, issue.12, pp.1101-1109, 2011.

J. M. Bliss, L. S. Kilburn, R. E. Coleman, J. F. Forbes, A. S. Coates et al., Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study, J Clin Oncol [Internet]. 1 mars, vol.30, issue.7, pp.709-726, 2012.

. Vidal, Monographie de l'ENANTONE (Leuproréline) LP 3,75 mg pdre/solv p susp inj LP IM/SC

. Disponible,

V. Monographie, Goséréline) 3,6 mg implant inj en seringue préremplie SC

. Disponible,

, Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane database Syst Rev

H. Pan, R. Gray, J. Braybrooke, C. Davies, C. Taylor et al., 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years, N Engl J Med, vol.377, issue.9, pp.1836-1882, 2017.

C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada et al., Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, vol.381, issue.9, pp.805-821, 2013.

. Disponible,

A. Eisen, M. Trudeau, W. Shelley, H. Messersmith, and K. I. Pritchard, Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review, Cancer Treat Rev [Internet]. avr, vol.34, issue.2, pp.157-74, 2008.

P. E. Goss, J. N. Ingle, K. I. Pritchard, N. J. Robert, H. Muss et al., Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years, N Engl J Med, vol.375, issue.3, pp.209-228, 2016.

Z. Yu, X. Guo, Y. Jiang, L. Teng, J. Luo et al., Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis. Breast Cancer, 2018.

J. Zhang, Y. Huang, C. Wang, Y. He, S. Zheng et al., Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. Med (United States, vol.96, pp.1-6, 2017.

A. M. Dnistrian, M. K. Schwartz, E. J. Greenberg, C. A. Smith, and D. C. Schwartz, Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy, Clin Chim Acta, vol.31, issue.1993, pp.43-52

C. Markopoulos, U. Dafni, J. Misitzis, V. Zobolas, E. Tzoracoleftherakis et al., Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy, R35. Disponible sur, vol.16

, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, vol.365, issue.9472, pp.1687-717, 2005.

C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada et al., Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, vol.381, issue.9, pp.805-821, 2013.

. Disponible,

E. Davies, C. Godwin, J. Gray, R. Clarke, M. Cutter et al., Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, vol.378, issue.9793, pp.771-84

. Who-working-group, Therapeutic Patient Education

, Education for Health: Change in Learning & Practice, vol.13, 2000.

. , 879 du 21 juillet 2009 portant réforme de l'hôpital et relative aux patients, à la santé et aux territoires Titre 3 article, p.84, 2009.

. Disponible,

, Décret n° 2010-906 du 2 août 2010 relatif aux compétences requises pour dispenser l'éducation thérapeutique du patient

, UNICANCER-Etude prospective-La cancérologie en 2025 : un patient et des soins connectés

. Disponible,

. République-française, Plan cancer, 2014.

, World Health Organization. Adherence to long-term therapies : Evidence for action

. Genève, , 2003.

. Disponible,

C. C. Murphy, L. K. Bartholomew, M. Y. Carpentier, S. M. Bluethmann, and S. W. Vernon, Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review, Breast Cancer Res Treat, vol.12, issue.2012, pp.459-78

L. Huiart, C. Ferdynus, and G. R. , A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians, Breast Cancer Res Treat [Internet], vol.12, issue.2013, pp.325-333

R. T. Chlebowski, J. Kim, and R. Haque, Adherence to endocrine therapy in breast cancer adjuvant and prevention settings, Cancer Prev Res, vol.1, issue.2014, pp.378-87

R. R. Love, L. Cameron, B. L. Connell, and H. Leventhal, Symptoms associated with tamoxifen treatment in postmenopausal women, Arch Intern Med, vol.151, issue.9, pp.1842-1849, 1991.

D. L. Hershman, L. H. Kushi, T. Shao, D. Buono, A. Kershenbaum et al., Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients, J Clin Oncol, vol.28, issue.20, pp.4120-4128, 2010.

O. Pagani, S. Gelber, M. Colleoni, K. N. Price, and E. Simoncini, Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials, pp.13-93

, Breast Cancer Res Treat, vol.142, issue.7, pp.455-464, 2013.

P. Fort, A. Dupuis, I. Princet, M. Albouy-llaty, and N. Raban, Vivre sous hormonothérapie après un cancer du sein : Les enjeux de l'éducation thérapeutique des patientes. Poitiers : Faculté de Médecine et de Pharmacie, 2013.

X. Girerd, O. Hanon, K. Anagnostopoulos, C. Ciupek, J. J. Mourad et al., Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic, Presse Med, vol.30, issue.21, pp.1044-1052

E. Manck and . Institut-curie, , 2017.

. Disponible,

R. T. Mathie, N. Ramparsad, L. A. Legg, J. Clausen, S. Moss et al., Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis, vol.6, p.63

R. T. Mathie, S. M. Lloyd, L. A. Legg, J. Clausen, S. Moss et al., Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis, vol.3, p.142

C. Jean-pierre-wainsten, Définition de la naturopathie, Larousse médical. Larousse, 2012.

H. Autorité-de-santé, Grille d'aide à l'évaluation de la demande d'autorisation par l'ARS

D. E. Morisky, A. Ang, M. Krousel-wood, and H. J. Ward, Predictive validity of a medication adherence measure in an outpatient setting, J Clin Hypertens